WO1996031208A3 - Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten - Google Patents

Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten Download PDF

Info

Publication number
WO1996031208A3
WO1996031208A3 PCT/EP1996/001442 EP9601442W WO9631208A3 WO 1996031208 A3 WO1996031208 A3 WO 1996031208A3 EP 9601442 W EP9601442 W EP 9601442W WO 9631208 A3 WO9631208 A3 WO 9631208A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted piperidine
pyrrolidine compounds
receptor modulated
modulated disorders
sigma
Prior art date
Application number
PCT/EP1996/001442
Other languages
English (en)
French (fr)
Other versions
WO1996031208A2 (de
Inventor
Norbert Kolassa
Johannes Kornhuber
Original Assignee
Byk Gulden Lomberg Chem Fab
Norbert Kolassa
Johannes Kornhuber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab, Norbert Kolassa, Johannes Kornhuber filed Critical Byk Gulden Lomberg Chem Fab
Priority to US08/930,642 priority Critical patent/US5994369A/en
Priority to EP96911993A priority patent/EP0819001A1/de
Priority to AU54993/96A priority patent/AU5499396A/en
Priority to JP8529973A priority patent/JPH11503140A/ja
Publication of WO1996031208A2 publication Critical patent/WO1996031208A2/de
Publication of WO1996031208A3 publication Critical patent/WO1996031208A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Verbindungen der Formel (I), worin R1, R2, R3, R4, R5, m und n die in der Beschreibung angegebenen Bedeutungen haben, zur Herstellung von Arzneimitteln für die Behandlung von Sigma-Rezeptor modulierten Krankheiten.
PCT/EP1996/001442 1995-04-05 1996-04-02 Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten WO1996031208A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/930,642 US5994369A (en) 1995-04-05 1996-04-02 Substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders
EP96911993A EP0819001A1 (de) 1995-04-05 1996-04-02 Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
AU54993/96A AU5499396A (en) 1995-04-05 1996-04-02 Use of substituted piperidine or pyrrolidine compounds for t reating sigma-receptor modulated disorders
JP8529973A JPH11503140A (ja) 1995-04-05 1996-04-02 シグマ−受容体が変調した疾患を治療するための、置換されたピペリジン化合物またはピロリジン化合物の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH97695 1995-04-05
CH976/95-1 1995-04-05

Publications (2)

Publication Number Publication Date
WO1996031208A2 WO1996031208A2 (de) 1996-10-10
WO1996031208A3 true WO1996031208A3 (de) 1996-11-14

Family

ID=4199588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/001442 WO1996031208A2 (de) 1995-04-05 1996-04-02 Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten

Country Status (5)

Country Link
US (1) US5994369A (de)
EP (1) EP0819001A1 (de)
JP (1) JPH11503140A (de)
AU (1) AU5499396A (de)
WO (1) WO1996031208A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19731521A1 (de) * 1997-07-23 1999-01-28 Byk Gulden Lomberg Chem Fab Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems
TW407153B (en) * 1997-10-27 2000-10-01 Nippon Kayaku Kk Imidazole compounds and their use
JP2001527038A (ja) * 1997-12-31 2001-12-25 セプラコール， インク． 尿失禁を治療するためのｒ−プロサイクリディン
CA2315843A1 (en) * 1997-12-31 1999-07-08 Sepracor Inc. S-procyclidine for treating urinary incontinence
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
AU770042B2 (en) * 1998-12-18 2004-02-12 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6897234B2 (en) * 1999-12-17 2005-05-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE60318306T2 (de) 2002-03-29 2008-12-11 Eisai R&D Management Co., Ltd. (1-indanon)-(1,2,3,6-tetrahydropyridin)derivat
US20070197389A1 (en) * 2004-02-25 2007-08-23 Anja Schwogler Azolopyrimidine compounds and use thereof for combating parasitic fungi
JP5436419B2 (ja) * 2008-06-04 2014-03-05 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 精神障害の治療方法および治療用医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000131A1 (en) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Sigma receptor ligands and the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000131A1 (en) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Sigma receptor ligands and the use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BECKMANN, H. ET AL: "The cholinolytic Biperiden in depression", ARCHIVES OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, vol. 231, no. 3, 1982, pages 213 - 220, XP002011683 *
HEATHCOTE, B.V. ET AL: "Pirenzepine selectively inhibits gastric acid secretion: a comparitive pharmacological study between pirenzepine and seven other antiacetylcholine drugs", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 15, no. 66, 1980, pages 15 - 26, XP002011684 *
HUDKINS RL ET AL: "M1 muscarinic antagonists interact with sigma recognition sites", LIFE SCI, 1991, 49 (17) P1229-35, ENGLAND, XP002011681 *
JELLINEK, T.: "Mood elevating effect of Trihexyphenidyl and Biperiden in individuals taking antipsychotic medication", DISEASES OF THE NERVOUS SYSTEM, vol. 38, no. 5, May 1977 (1977-05-01), pages 353 - 355, XP002011682 *
VOGELS, O.J.M. ET AL: "Focal dystonia and speech impairment responding to anticholinergic therapy", PAEDIATRIC NEUROLOGY, vol. 11, no. 4, November 1994 (1994-11-01), pages 346 - 348, XP002011685 *

Also Published As

Publication number Publication date
JPH11503140A (ja) 1999-03-23
EP0819001A1 (de) 1998-01-21
WO1996031208A2 (de) 1996-10-10
AU5499396A (en) 1996-10-23
US5994369A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
AU674477B2 (en) Heterocyclic-cyclic amine derivatives
MX9709240A (es) Fenilpiridazinonas.
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
BG103485A (en) Ketobanzamides as calpain inhibitors
DE69434313D1 (de) Superoxiddismutase memetika
AU3115395A (en) Dihydrobenzofuranes
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
BG101110A (en) Substituted pyrimidine compounds and their application
EP0807633A3 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
CA2199844A1 (en) Compositions for the treatment of skin disorders
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
MX9709398A (es) N-aril-1,2,4-triazolin-5-onas.
WO1996031208A3 (de) Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
EP1121932A4 (de) Heilmittel für augenerkrankungen
AU7381991A (en) Hydroxymethyl-indolizidines and quinolizidines
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
WO2000011951A3 (de) Verwendung von 5-amino-pyrazol-derivaten zur bekämpfung von mikrooranismen
AU2796695A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
EP0928792A3 (de) Bicyclische(3.1.0)hexane und verwandte Verbindungen
PE61999A1 (es) Compuestos de tetrahidropiridina
PL346003A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BY CA CN CZ EE HU JP KR LT LV MX NO NZ PL RO RU SG SI SK UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BY CA CN CZ EE HU JP KR LT LV MX NO NZ PL RO RU SG SI SK UA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996911993

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 529973

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 08930642

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996911993

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996911993

Country of ref document: EP